Real-world use of empaglifozin and dapaglifozin in patients with HEART failure

dc.contributor.authorKocabas, U. Uumut
dc.contributor.authorYavuz, V.
dc.contributor.authorAltin, C.
dc.contributor.authorKaplan, M.
dc.contributor.authorOztekin, G. M. Yilmaz
dc.contributor.authorDogdus, M.
dc.contributor.authorOzcalik, E.
dc.date.accessioned2026-08-12T18:13:26Z
dc.date.issued2024
dc.departmentFırat Üniversitesi
dc.description.abstract[Abstract Not Available]
dc.identifier.endpage410
dc.identifier.issn1388-9842
dc.identifier.issn1879-0844
dc.identifier.startpage410
dc.identifier.urihttps://hdl.handle.net/11508/64404
dc.identifier.volume26
dc.identifier.wosWOS:001290635503131
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofEuropean Journal of Heart Failure
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.titleReal-world use of empaglifozin and dapaglifozin in patients with HEART failure
dc.typeConference Object

Dosyalar